Clinical Trials
27 trialsClinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Fox Chase Cancer Center
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
BREASTIMMU02
Centre Leon Berard
ANISE
The Netherlands Cancer Institute
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
University of Rochester
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
National Cancer Centre, Singapore
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
HER2-DM-NACT
Hebei Medical University Fourth Hospital
TUC-TOC
Institut Curie
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
First Affiliated Hospital of Zhejiang University
GeparPiPPa
GBG Forschungs GmbH
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
Fudan University
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
Cancer Trials Ireland
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
First Affiliated Hospital Xi'an Jiaotong University
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer
ChineseAMS
HERMET
University of Kansas Medical Center
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
Peking University
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
ChineseAMS
SHERO
Second Affiliated Hospital, School of Medicine, Zhejiang University
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study
Hebei Medical University Fourth Hospital
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Shandong Cancer Hospital and Institute